The partnership was formed in September 2024 in response to increasing demand for aseptic filling technologies and processes.

Hikma Pharmaceuticals. Hikma Pharmaceuticals USA Announces $1 Billion of New US Investment to Further Expand its Domestic ...

The new building expands on the company’s supply chain solutions for biologics and temperature-sensitive pharmaceuticals.

The company’s mocravimod, a novel oral S1P receptor, is being evaluated for its efficacy as an addition to CAR-T cell ...

In this episode of the Ask the Expert video series, Simona Guidi, Associate Director, Cell and Gene Therapies at ProPharma, ...

Cambridge Healthcare Innovations says its dry powder inhaler engine, Quattrii, can deliver large volumes of biologic and mRNA ...

Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...

The following six biosimilars were given a positive opinion at the June meeting: treatments for treatment of age-related macular degeneration and visual impairment: Mynzepli (aflibercept), and its ...

The department’s newly announced partnerships were part of a weeklong visit that included discussions held at BIO 2025.